New compounds target viral sugars, blocking infections

Researchers have identified compounds that target viral envelope glycans, offering a potential path to the world's first broad-spectrum antiviral. The study identified four compounds that successfully blocked infection from seven different viruses, including Ebola and SARS-CoV-2, by binding to these shared sugar molecules. This breakthrough could provide a crucial first line of defense against emerging viral threats, with promising results seen in mouse models.